FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200019259> ?p ?o ?g. }

• W4200019259 endingPage "142" @default.
• W4200019259 startingPage "142" @default.
• W4200019259 abstract "Clinical trial populations may not reflect clinical practice: knowledge generated in other settings can inform clinical decision-making.To evaluate self-reported disease control and quality of life after initiating dupilumab treatment in patients with atopic dermatitis (AD) in the the clinical setting.This cohort study using an online survey administered prior to (baseline) and at 1, 2, 3, 6, 9, and 12 months after dupilumab initiation included adults with moderate-to-severe AD who initiated treatment with dupilumab through the US patient support program and agreed to participate in the study. Data were collected between January 2018 and January 2020 and the analysis was completed in May 2020.Clinically driven treatment with dupilumab.Disease control measured by the Atopic Dermatitis Control Tool (ADCT); concomitant AD therapies; satisfaction with therapy; skin symptoms (skin pain/soreness, hot/burning feeling, sensitivity to touch) assessed using numerical rating scales; flares; health-related quality of life assessed using the Dermatology Life Quality Index; sleep problems assessed using the ADCT item and a stand-alone question; and the AD-specific Work Productivity and Activity Impairment Questionnaire.Of 699 patients who initiated dupilumab (431 [61.7%] female, 515 [73.7%] White), 632 and 483 completed the survey at months 1 and 12, respectively. As-observed results showed that most patients achieved adequate disease control (ADCT total score) at month 1 with further improvement at month 12 (385 of 632 patients [60.9%] and 374 of 483 [77.4%] for the 2 time points, respectively, vs 41 of 699 [5.3%] at baseline; both P < .001). Use of other AD therapies was reduced at each follow-up vs baseline, including topical and systemic corticosteroids, which were reduced at month 12 to 40.4% (195 of 483 patients) and 6.2% (30 of 483 patients), respectively, from 68.1% (476 of 699) and 34.9% (244 of 699), respectively, at baseline (both P < .001 vs baseline). Patient satisfaction with AD treatment was higher than baseline (120 of 699 [17.7%]) at each follow-up to 85.1% (411 of 483) at month 12 (P < .001). At each follow-up, patients reported reductions in flares, itch, skin symptoms, and improved sleep, health-related quality of life, and daily activities vs baseline. Results were consistent based on observed data and imputed data using pattern mixture models for missing data.Consistent with patient-reported outcomes in clinical trials, this cohort study found that dupilumab treatment was associated with rapid and sustained disease control for up to 12 months as demonstrated by statistically significant improvements relative to baseline on all patient-reported outcomes including treatment satisfaction." @default.
• W4200019259 created "2021-12-31" @default.
• W4200019259 creator A5026566958 @default.
• W4200019259 creator A5032408333 @default.
• W4200019259 creator A5044300803 @default.
• W4200019259 creator A5065566858 @default.
• W4200019259 creator A5068662580 @default.
• W4200019259 creator A5070289938 @default.
• W4200019259 creator A5073499085 @default.
• W4200019259 creator A5077097587 @default.
• W4200019259 creator A5091485944 @default.
• W4200019259 date "2022-02-01" @default.
• W4200019259 modified "2023-10-18" @default.
• W4200019259 title "Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis" @default.
• W4200019259 cites W2012868073 @default.
• W4200019259 cites W2058562555 @default.
• W4200019259 cites W2096391232 @default.
• W4200019259 cites W2155349756 @default.
• W4200019259 cites W2161414087 @default.
• W4200019259 cites W2174132185 @default.
• W4200019259 cites W2200308911 @default.
• W4200019259 cites W2300630231 @default.
• W4200019259 cites W2419580390 @default.
• W4200019259 cites W2473354825 @default.
• W4200019259 cites W2524051065 @default.
• W4200019259 cites W2610814011 @default.
• W4200019259 cites W2613379575 @default.
• W4200019259 cites W2762211612 @default.
• W4200019259 cites W2765668367 @default.
• W4200019259 cites W2772411615 @default.
• W4200019259 cites W2888777463 @default.
• W4200019259 cites W2888917798 @default.
• W4200019259 cites W2892288216 @default.
• W4200019259 cites W2893746817 @default.
• W4200019259 cites W2896539902 @default.
• W4200019259 cites W2916087813 @default.
• W4200019259 cites W2958557460 @default.
• W4200019259 cites W2965009353 @default.
• W4200019259 cites W2981702922 @default.
• W4200019259 cites W2986029043 @default.
• W4200019259 cites W2988092601 @default.
• W4200019259 cites W2990969378 @default.
• W4200019259 cites W3036639957 @default.
• W4200019259 cites W3178810292 @default.
• W4200019259 cites W4229971158 @default.
• W4200019259 cites W4231580791 @default.
• W4200019259 cites W4232746932 @default.
• W4200019259 cites W4232889407 @default.
• W4200019259 cites W4236548038 @default.
• W4200019259 cites W4236577907 @default.
• W4200019259 cites W4239202591 @default.
• W4200019259 cites W4241802495 @default.
• W4200019259 cites W4246930005 @default.
• W4200019259 cites W4247795726 @default.
• W4200019259 cites W4248872865 @default.
• W4200019259 cites W4249135956 @default.
• W4200019259 cites W4251717578 @default.
• W4200019259 cites W4252040170 @default.
• W4200019259 doi "https://doi.org/10.1001/jamadermatol.2021.4778" @default.
• W4200019259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34910086" @default.
• W4200019259 hasPublicationYear "2022" @default.
• W4200019259 type Work @default.
• W4200019259 citedByCount "6" @default.
• W4200019259 countsByYear W42000192592022 @default.
• W4200019259 countsByYear W42000192592023 @default.
• W4200019259 crossrefType "journal-article" @default.
• W4200019259 hasAuthorship W4200019259A5026566958 @default.
• W4200019259 hasAuthorship W4200019259A5032408333 @default.
• W4200019259 hasAuthorship W4200019259A5044300803 @default.
• W4200019259 hasAuthorship W4200019259A5065566858 @default.
• W4200019259 hasAuthorship W4200019259A5068662580 @default.
• W4200019259 hasAuthorship W4200019259A5070289938 @default.
• W4200019259 hasAuthorship W4200019259A5073499085 @default.
• W4200019259 hasAuthorship W4200019259A5077097587 @default.
• W4200019259 hasAuthorship W4200019259A5091485944 @default.
• W4200019259 hasConcept C126322002 @default.
• W4200019259 hasConcept C159110408 @default.
• W4200019259 hasConcept C16005928 @default.
• W4200019259 hasConcept C1862650 @default.
• W4200019259 hasConcept C205545832 @default.
• W4200019259 hasConcept C2776173921 @default.
• W4200019259 hasConcept C2778329239 @default.
• W4200019259 hasConcept C2779134260 @default.
• W4200019259 hasConcept C2779384505 @default.
• W4200019259 hasConcept C2779824493 @default.
• W4200019259 hasConcept C2779951463 @default.
• W4200019259 hasConcept C2780699399 @default.
• W4200019259 hasConcept C71924100 @default.
• W4200019259 hasConcept C72563966 @default.
• W4200019259 hasConceptScore W4200019259C126322002 @default.
• W4200019259 hasConceptScore W4200019259C159110408 @default.
• W4200019259 hasConceptScore W4200019259C16005928 @default.
• W4200019259 hasConceptScore W4200019259C1862650 @default.
• W4200019259 hasConceptScore W4200019259C205545832 @default.
• W4200019259 hasConceptScore W4200019259C2776173921 @default.
• W4200019259 hasConceptScore W4200019259C2778329239 @default.
• W4200019259 hasConceptScore W4200019259C2779134260 @default.
• W4200019259 hasConceptScore W4200019259C2779384505 @default.

• next